Dana-Farber’s revolutionary discoveries are changing cancer treatment everywhere.

Dana-Farber has played a foundational role in more than half of the cancer drugs approved by the FDA.

Data from 2020-2024

What we learn about cancer in the lab we turn against cancer in the clinic, and vice versa. These discoveries ripple across the cancer landscape.

PD-L1 AND CTLA-4 PATHWAYS

F. Stephen Hodi, Jr., MD
Gordon J. Freeman, PhD

video
NOBEL PRIZE WINNING RESEARCH

William G. Kaelin Jr., MD

video
CDK4/6 INHIBITORS

Geoffrey Shapiro, MD, PhD
Peter Sicinski, MD, PhD
Erica L. Mayer, MD, MPH

audio

What we do here
changes lives everywhere

When you follow the science, one thing leads to another. A new insight takes a previous breakthrough further. Thanks to our momentum of discovery, living with cancer is less of a burden, and living without cancer is a greater possibility.

What’s the story behind some of Dana-Farber’s most remarkable discoveries? This podcast series takes you deeper.

Explore the latest Dana-Farber advances in cancer medicine designed for medical professionals.

One cancer discovery after another for over 75 years.

Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high...

Learn more >

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of...

Learn more >

FDA approves menin inhibitor for patients with acute leukemia with NPM1 mutation, backed by Dana-Farber science

The U.S. Food and Drug Administration (FDA) approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory acute myeloid leukemia (AML) with NPM1 gene mutations. Revu...

Learn more >

FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs). This represents a new standard of care ther...

Learn more >

FDA approves new therapy for glioma patients for first time in decades

Based on results of the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, the newly approved drug vorasidenib could delay the need for radiation and chemotherapy for patients with IDH-mutant glioma.

Learn more >

Dana-Farber’s revolutionary discoveries are changing cancer treatment everywhere.

Dana-Farber has played a foundational role in more than half of the cancer drugs approved by the FDA.

What we learn about cancer in the lab we turn against cancer in the clinic, and vice versa. These discoveries ripple across the cancer landscape.

PD-L1 AND CTLA-4 PATHWAYS

NOBEL PRIZE WINNING RESEARCH

CDK4/6 INHIBITORS

What we do herechanges lives everywhere

One cancer discovery after another for over 75 years.

Dana-Farber has played a foundational role in more than half of the cancer drugs approved by the FDA.

What we do here
changes lives everywhere